Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection

[1]  M. Ratajczak,et al.  Overlapping and distinct role of CXCR7‐SDF‐1/ITAC and CXCR4‐SDF‐1 axes in regulating metastatic behavior of human rhabdomyosarcomas , 2010, International journal of cancer.

[2]  D. Giuffrida,et al.  Targeting cancer stem cell lines as a new treatment of human cancer. , 2010, Recent patents on anti-cancer drug discovery.

[3]  Kenya Yoshida,et al.  Knockdown of ZEB1, a master epithelial-to-mesenchymal transition (EMT) gene, suppresses anchorage-independent cell growth of lung cancer cells. , 2010, Cancer letters.

[4]  F. Marshall,et al.  Phorbol ester phorbol‐12‐myristate‐13‐acetate induces epithelial to mesenchymal transition in human prostate cancer ARCaPE cells , 2010, The Prostate.

[5]  C. Gargett,et al.  A cancer stem cell origin for human endometrial carcinoma? , 2010, Reproduction.

[6]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[7]  N. Hayashi,et al.  Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma. , 2010, Journal of hepatology.

[8]  O. Olopade,et al.  Stem Cells , Tissue Engineering and Hematopoietic Elements Wnt /-Catenin Pathway Activation Is Enriched in Basal-Like Breast Cancers and Predicts Poor Outcome , 2010 .

[9]  M. Honda,et al.  Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. , 2010, Cancer research.

[10]  Xin-yang Wang,et al.  Silibinin reverses epithelial-to-mesenchymal transition in metastatic prostate cancer cells by targeting transcription factors. , 2010, Oncology reports.

[11]  Guohua Zhang,et al.  Wnt signaling may be activated in a subset of Peutz-Jeghers syndrome polyps closely correlating to LKB1 expression. , 2010, Oncology reports.

[12]  Steven J. Greco,et al.  Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-β , 2010, The Journal of Immunology.

[13]  Jenny G. Parvani,et al.  The Pathophysiology of Epithelial-Mesenchymal Transition Induced by Transforming Growth Factor-β in Normal and Malignant Mammary Epithelial Cells , 2010, Journal of Mammary Gland Biology and Neoplasia.

[14]  M. Herlyn,et al.  Epidermal growth factor receptor and mutant p53 expand an esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB transcription factors. , 2010, Cancer research.

[15]  E. Leygue,et al.  Claudin 1 in Breast Tumorigenesis: Revelation of a Possible Novel “Claudin High” Subset of Breast Cancers , 2010, Journal of biomedicine & biotechnology.

[16]  P. Humbert,et al.  Cell Polarity in Motion: Redefining Mammary Tissue Organization Through EMT and Cell Polarity Transitions , 2010, Journal of Mammary Gland Biology and Neoplasia.

[17]  M. Fishbein,et al.  The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC , 2010, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[18]  E. Yu,et al.  Prognostic significance of number of positive nodes: a long-term study of one to two nodes versus three nodes in breast cancer patients. , 2010, International journal of radiation oncology, biology, physics.

[19]  M. Quinn,et al.  Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. , 2010, Current cancer drug targets.

[20]  K. Tanimoto,et al.  Carcinogenesis and cellular immortalization without persistent inactivation of p16/Rb pathway in lung cancer. , 2010, International journal of oncology.

[21]  Camille Stephan-Otto Attolini,et al.  A Differentiation-Based Phylogeny of Cancer Subtypes , 2010, PLoS Comput. Biol..

[22]  Kai Huang,et al.  Vimentin Is a Novel Anti-Cancer Therapeutic Target; Insights from In Vitro and In Vivo Mice Xenograft Studies , 2010, PloS one.

[23]  L. Wessels,et al.  Molecular subtyping of breast cancer: ready to use? , 2010, The Lancet. Oncology.

[24]  I. Sánchez-García,et al.  Cancer as a reprogramming-like disease: implications in tumor development and treatment. , 2010, Seminars in cancer biology.

[25]  Jie Luo,et al.  Stem Cells in Normal Mammary Gland and Breast Cancer , 2010, The American journal of the medical sciences.

[26]  R. Keri,et al.  Krüppel-like Factor 4 Inhibits Epithelial-to-Mesenchymal Transition through Regulation of E-cadherin Gene Expression* , 2010, The Journal of Biological Chemistry.

[27]  Michael L. Gatza,et al.  A pathway-based classification of human breast cancer , 2010, Proceedings of the National Academy of Sciences.

[28]  C. Blanpain,et al.  Identification of the cell lineage at the origin of basal cell carcinoma , 2010, Nature Cell Biology.

[29]  B. Groner,et al.  Stem Cells of the Breast and Cancer Therapy , 2010, Women's health.

[30]  Mei Zhang,et al.  Selective targeting of radiation-resistant tumor-initiating cells , 2010, Proceedings of the National Academy of Sciences.

[31]  S. Thorgeirsson,et al.  Stem Cells in Hepatocarcinogenesis: Evidence from Genomic Data , 2010, Seminars in liver disease.

[32]  K. Camphausen,et al.  Cancer stem cells as a prognostic indicator for glioblastoma multiforme. , 2010, Biomarkers in Medicine.

[33]  S. Shi,et al.  Mesenchymal stem cells derived from human gingiva are capable of immunomodulatory functions and ameliorate inflammation-related tissue destruction in experimental colitis , 2010, The Journal of Immunology.

[34]  M. Hermanová,et al.  Influence of LOX/COX inhibitors on cell differentiation induced by all-trans retinoic acid in neuroblastoma cell lines. , 2009, International journal of molecular medicine.

[35]  A. Friedl,et al.  Heterogeneity of Gene Expression in Stromal Fibroblasts of Human Breast Carcinomas and Normal Breast , 2009, Oncogene.

[36]  W. Helfrich,et al.  Targeted elimination of leukemia stem cells; a new therapeutic approach in hemato-oncology. , 2010, Current drug targets.

[37]  Cheng-Hai Liu,et al.  Salvianolic acid B prevents epithelial-to-mesenchymal transition through the TGF-β1 signal transduction pathway in vivo and in vitro , 2010, BMC Cell Biology.

[38]  Ekaterina I. Galanzha,et al.  Nanotechnology‐based molecular photoacoustic and photothermal flow cytometry platform for in‐vivo detection and killing of circulating cancer stem cells , 2009, Journal of biophotonics.

[39]  G. Berx,et al.  Involvement of members of the cadherin superfamily in cancer. , 2009, Cold Spring Harbor perspectives in biology.

[40]  C. Shih,et al.  Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells. , 2009, Cancer research.

[41]  Y. Toiyama,et al.  Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. , 2009, Oncology reports.

[42]  A. Eljaafari,et al.  Mesenchymal stem cells protect NOD mice from diabetes by inducing regulatory T cells , 2009, Diabetologia.

[43]  M. Büchler,et al.  Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma , 2009, Journal of cellular and molecular medicine.

[44]  Manuel A. González,et al.  Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. , 2009, Arthritis and rheumatism.

[45]  Seong-Doo Hong,et al.  Inhibition of Akt activity induces the mesenchymal-to-epithelial reverting transition with restoring E-cadherin expression in KB and KOSCC-25B oral squamous cell carcinoma cells , 2009, Journal of experimental & clinical cancer research : CR.

[46]  I. Haviv,et al.  Origin of carcinoma associated fibroblasts , 2009, Cell cycle.

[47]  M. Sperandio,et al.  Plerixafor inhibits chemotaxis toward SDF-1 and CXCR4-mediated stroma contact in a dose-dependent manner resulting in increased susceptibility of BCR-ABL+ cell to Imatinib and Nilotinib , 2009, Leukemia & lymphoma.

[48]  W. Schroth,et al.  Highly variable response to cytotoxic chemotherapy in carcinoma-associated fibroblasts (CAFs) from lung and breast , 2008, BMC Cancer.

[49]  A. Friedl,et al.  Membrane type 1 matrix metalloproteinase-mediated stromal syndecan-1 shedding stimulates breast carcinoma cell proliferation. , 2008, Cancer research.

[50]  J. McCubrey,et al.  Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. , 2008, Cancer research.

[51]  N. Perico,et al.  Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells1 , 2008, The Journal of Immunology.

[52]  J. Mesirov,et al.  Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells. , 2008, Cancer research.

[53]  Jae Hyun Kim,et al.  Cancer‐Derived Lysophosphatidic Acid Stimulates Differentiation of Human Mesenchymal Stem Cells to Myofibroblast‐Like Cells , 2008, Stem cells.

[54]  A. Tabilio,et al.  Mesenchymal cells recruit and regulate T regulatory cells. , 2008, Experimental hematology.

[55]  N. Rouas-Freiss,et al.  Human Leukocyte Antigen‐G5 Secretion by Human Mesenchymal Stem Cells Is Required to Suppress T Lymphocyte and Natural Killer Function and to Induce CD4+CD25highFOXP3+ Regulatory T Cells , 2008, Stem cells.

[56]  C. Perou,et al.  Epidemiology of basal-like breast cancer , 2008, Breast Cancer Research and Treatment.

[57]  P. Virkkunen,et al.  Oncolytic adenoviruses kill breast cancer initiating CD44+CD24-/low cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[58]  Ross Tubo,et al.  Mesenchymal stem cells within tumour stroma promote breast cancer metastasis , 2007, Nature.

[59]  Chang-Guo Zhan,et al.  The tumor inhibitor and antiangiogenic agent withaferin A targets the intermediate filament protein vimentin. , 2007, Chemistry & biology.

[60]  E. Thompson,et al.  Mesenchymal to Epithelial Transition in Development and Disease , 2007, Cells Tissues Organs.

[61]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[62]  C. Perou,et al.  Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.

[63]  S. Phan,et al.  The extrapulmonary origin of fibroblasts: stem/progenitor cells and beyond. , 2006, Proceedings of the American Thoracic Society.

[64]  H. Minamiguchi,et al.  Hematopoietic origins of fibroblasts: I. In vivo studies of fibroblasts associated with solid tumors. , 2006, Experimental hematology.

[65]  L. Wakefield,et al.  TGF-β switches from tumor suppressor to prometastatic factor in a model of breast cancer progression , 2003 .

[66]  P. Rameshwar,et al.  Veto-Like Activity of Mesenchymal Stem Cells: Functional Discrimination Between Cellular Responses to Alloantigens and Recall Antigens1 , 2003, The Journal of Immunology.

[67]  L. Wakefield,et al.  TGF-beta switches from tumor suppressor to prometastatic factor in a model of breast cancer progression. , 2003, The Journal of clinical investigation.

[68]  L. Wakefield,et al.  Lifetime exposure to a soluble TGF-beta antagonist protects mice against metastasis without adverse side effects. , 2002, The Journal of clinical investigation.

[69]  I. Weissman,et al.  Stem cells, cancer, and cancer stem cells , 2001, Nature.

[70]  R. Baynes,et al.  High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: past or future? , 2001, Seminars in oncology.

[71]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[72]  S Paget,et al.  THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .

[73]  J. Bingham.  Letter: Lower oesophageal sphincter. , 1974, Lancet.